STOCK TITAN
  1. Home
  2. News
  3. DARE

Dare Bioscience Inc - DARE STOCK NEWS

Welcome to our dedicated news page for Dare Bioscience (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dare Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dare Bioscience's position in the market.

News
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Rhea-AI Summary
Daré Bioscience receives $1 million grant funding installment to advance development of DARE-LARC1 contraceptive technology. The potential contraceptive aims to offer women control over fertility with precision dosing, extended duration, and wireless control. The technology, developed by renowned researchers, has the potential to address unmet needs in reproductive health and other therapeutic areas like diabetes and obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Rhea-AI Summary
Daré Bioscience, Inc. announces positive results from postcoital test study of Ovaprene, a hormone-free monthly intravaginal contraceptive for women. The study demonstrated safety and efficacy, with Ovaprene preventing sperm entry without disrupting the vaginal microbiome. The pivotal Phase 3 clinical study is currently enrolling participants across the U.S. with the potential to support marketing approvals of Ovaprene in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
-
News
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Rhea-AI Summary
Daré Bioscience, Inc. reported financial results for 2023, highlighting the availability of XACIATO™ for bacterial vaginosis treatment, progress on Ovaprene® contraceptive candidate Phase 3 study, and successful completion of end-of-Phase 2 meeting for Sildenafil Cream. The company is optimistic about achieving significant milestones in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.71%
Tags
earnings
News
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Rhea-AI Summary
Daré Bioscience, Inc. (DARE) to host a conference call to discuss financial results for the year ended December 31, 2023, and provide a company update on March 28, 2024, at 4:30 p.m. Eastern Time. Investors can access the call via phone or live webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
conferences earnings
-
News
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
Rhea-AI Summary
Daré Bioscience, Inc. (NASDAQ: DARE) reveals promising data from the Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, showing increased sexual events frequency and improvements in various aspects of the sexual experience for women with female sexual arousal disorder. The company aims to move towards a Phase 3 pivotal study to address the lack of FDA-approved treatments for FSAD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.55%
Tags
conferences
-
News
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Rhea-AI Summary
Daré Bioscience, Inc. (NASDAQ: DARE) and Strategic Science & Technologies, LLC announced the successful completion of an end-of-Phase 2 meeting with the FDA, supporting the advancement of Sildenafil Cream, 3.6% for the treatment of female sexual arousal disorder (FSAD) to a Phase 3 clinical study. The FDA confirmed that FSAD is an acceptable indication for the trials and that 12-weeks of blinded treatment may be acceptable. Positive data from the Phase 2b RESPOND clinical study supported the meeting, identifying the subgroup of patients most likely to benefit from therapy and achieve meaningful improvement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
clinical trial
News
Daré Bioscience Announces Executive Team and Board of Directors Changes
Rhea-AI Summary
Daré Bioscience, Inc. announced changes in company management, including the retirement of the Chief Financial Officer and the resignation of the Chief Commercial Officer. The company also made adjustments to the size of its Board of Directors. The retirement of the CFO will lead to a transition in responsibilities, with the CEO taking over as the principal financial officer and a new Chief Accounting Officer being appointed. The resignation of the Chief Commercial Officer is in line with the full-scale commercial launch of XACIATO™. The Board of Directors also underwent a reduction in size to better reflect the company's operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Rhea-AI Summary
Daré Bioscience, Inc. (NASDAQ: DARE) has received a $750,000 grant from the Bill & Melinda Gates Foundation to fund activities related to bacteria-based live biotherapeutic product development. This grant is intended to cover the costs of gathering and analyzing data on the global bacterial biologic supply chain to help the foundation identify potential Contract Manufacturing Organization (CMO) partners for manufacturing clinical and commercial supplies of bacteria-based biotherapeutic products. The grant aims to benefit women and newborns as the primary patient populations for interventions where bacteria consortia products are an important modality in the therapeutic arsenal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
-
News
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Rhea-AI Summary
Dare Bioscience, Inc. (NASDAQ: DARE) achieves technological proof of concept for DARE-LARC1, a long-acting contraceptive device with potential applications in diabetes, obesity, and other conditions requiring precise and prolonged treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.31%
Tags
none
News
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
Rhea-AI Summary
Daré Bioscience, Inc. (NASDAQ: DARE) secures $5 million at closing and up to $7 million of additional funding through a royalty-backed financing agreement. The investor is entitled to a percentage of royalties and milestones from Daré's global license agreement for XACIATO™ with Organon. The financing aims to drive shareholder value and advance late-stage product candidates, with the potential for Daré to terminate the agreement and revert future payments once the investor achieves a targeted return on investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
none
Stock DARE logo
Dare Bioscience Inc

Nasdaq:DARE

DARE Rankings

#4986 Ranked by Market Cap
#4833 Ranked by Stock Gains
N/A Ranked by Dividends

DARE Stock Data

47.21M
98.89M
1.65%
6.63%
0.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Diego

About DARE

daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.